Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 7/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.36 |
| ▸ | CDK4 | P11802 | 3/20 | 0.34 |
| ▸ | CCND1 | P24385 | 2/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15035686 | 0.93 | CDK4 (0.35) | MAPK8PTK2CDK4CCND1CCNA2 | |
| SCHEMBL15041413 | 0.86 | MAPK14 (0.39) | MAPK14MAPK8PTK2CDK4CCND1 | |
| SCHEMBL15041361 | 0.81 | MAPK14 (0.38) | MAPK14MAPK8PTK2CDK4CCND1 | |
| SCHEMBL15041396 | 0.80 | MAPK14 (0.40) | MAPK14MAPK8PTK2 | |
| SCHEMBL15035898 | 0.79 | CDK4 (0.37) | MAPK8PTK2CDK4CCND1CCNA2 | |
| SCHEMBL15041225 | 0.78 | MAPK14 (0.43) | MAPK14MAPK8PTK2CDK4CCND1 | |
| SCHEMBL15041835 | 0.78 | PTK2 (0.42) | MAPK14MAPK8PTK2CDK4 | |
| SCHEMBL15041609 | 0.74 | MAPK8 (0.40) | MAPK14MAPK8 | |
| SCHEMBL15034818 | 0.73 | PTK2 (0.36) | PTK2CDK4CCND1CCNA2CDK2 | |
| SCHEMBL15035036 | 0.73 | TNK2 (0.36) | MAPK8PTK2CDK4CCND1CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130252967-A1 | 8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252967-A1 | 8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | PAK2, PAK3, PAK6 | MAPK14 111/4885MAPK8 8/4885PTK2 166/4885 |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | MAPK14 382/4885MAPK8 493/4885PTK2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.